RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Posted 01 December 2008

On 24 July 2008, on its earnings call, Eli Lilly and Company announced its intention to partner with TPG-Axon and NovaQuest for the development of Lilly's two lead molecules for the treatment of Alzheimer's disease.1 One molecule is a gamma-secretase small molecule and the other is an antibody targeted against A-beta. Both molecules are designed to modify the progression of mild to moderate Alzheimer's disease.

 

© 2022 Regulatory Affairs Professionals Society.